Dimopoulos M, Tedeschi A, Trotman J, et al. Multinational, randomized phase 3 trial of ibrutinib-rituximab vs placebo-rituximab with Waldenström’s macroglobulinemia. EHA 2018, abstract S852.
Resultaten Admiral-studie: EMA-goedkeuring gilteritinib AML met FLT3-mutatie
dec 2019 | Leukemie